Morgan Stanley says REDEFINE-2 misses opportunity to differentiate in diabetes
Morgan Stanley notes Novo Nordisk (NVO) disclosed headline data for CagriSema in REDEFINE-2, with a weight loss and safety ...
pharmaphorum1mon
Novo charts course ahead for CagriSema after lacklustre data
Novo Nordisk has acknowledged that the first phase 3 readout for new obesity hopeful CagriSema was hard to interpret and disappointed investors, but it has a plan to revitalise the programme.
Reuters1mon
Novo Nordisk's next-gen obesity drug Cagrisema: investors seek answers
LONDON/SAN FRANCISCO, Feb 4 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab is under pressure from investors for more information about its next-generation obesity drug candidate CagriSema amid ...
WebMD19d
What Drugs Are Being Researched for Obesity?
CagriSema combines the GLP-1 receptor agonist semaglutide with cagrilintide, a drug that acts like the blood sugar-controlling hormone amylin. Researchers are testing CagriSema as a treatment for ...
BioSpace8d
Obesity Late-Comer AbbVie Inks Up to $2.2B Amylin Deal With Gubra
AbbVie on Monday jumped into the hot weight-loss space, looking to gain ground on its Big Pharma peers, with a licensing deal ...
Hosted on MSN1mon
Amycretin Shows Promising 22% Weight Loss in Trials-It May Rival Ozempic
Novo Nordisk, the manufacturer of both, recently shared that CagriSema may lead to 10 percent ... "Given the current data, amycretin may affect the mechanism of the gut-brain axis and has an ...
Seeking Alpha26d
Novo Nordisk: Dips Like These Come Once Every Few Years
Novo Nordisk shares have dropped significantly in December due to disappointing CagriSema trial results, but not everything from those results was negative. Amycretin's promising early-stage ...